Artax Biopharma's AX-158: A Novel Approach to T Cell-Driven Inflammation in Psoriasis
Risankizumab Effective in Difficult-to-Treat Psoriasis Areas
Practice and Personal Planning: Tactics That Reduce Taxes and Protect Assets
Daily Derm Times: May 14, 2025